Crohn’s disease patient-derived intestinal organoids were characterized by differentiation gene markers and then exposed to TNF-α, IFN-γ, IL-1β or LPS, or IL-28A with or without GLPG0634.
[American Journal of Physiology-Gastrointestinal and Liver Physiology]
6445218 DPCMQNDI items 1 apa default asc 1
Xu, P., Becker, H., Elizalde, M., Pierik, M., Masclee, A. A. M., & Jonkers, D. M. A. E. (2021). Interleukin-28A Induces Epithelial Barrier Dysfunction in CD Patient-derived Intestinal Organoids. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00064.2020 Cite
Scientists present an overview of the current knowledge of colitis-associated cancer (CAC) in inflammatory bowel disease (IBD) patients, focusing on the role of inflammation in the pathogenesis of CAC and the potential for IBD drugs to interfere with the process of carcinogenesis by reducing the inflammatory process or by modulating pathways directly involved in carcinogenesis.
[Digestive and Liver Disease]
1254621 WXST2YCD items 1 apa default asc 1
Paneth cells are located at the base of small intestinal crypts and secrete the α‐defensins, human α‐defensin 5 and human α‐defensin 6 in response to bacterial, cholinergic and other stimuli.
1254621 ILTZBYE7 items 1 apa default asc 1
Investigators compared the inflammatory phenotype of monocytes from Crohn’s disease patients, who responded or non-responded to infliximab. Under basal conditions, the mRNA for the cytokines TNFα, IL-23, IL-1β and the chemokines CXCL8/IL-8, CCL5/RANTES and CCL2/MCP-1 was up-regulated in monocytes from non-responders than responders.
Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the FDA has approved Hulio® for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.
6606345 BH5ME85A items 1 apa default asc 1
This study demonstrated that inhibition of AXL signaling with the small molecule inhibitor BGB324 abrogated both matrix-stiffness and transforming growth factor beta–induced fibrogenesis in human colonic myofibroblasts.
[Inflammatory Bowel Diseases]
6606345 ES3PR5GV items 1 apa default asc 1
UCB and Ferring Pharmaceuticals Inc. announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA® in the United States, specifically for the treatment of Crohn’s disease.
Using a strain of congenic SAMP mice engineered to lack global expression of ERβ, investigators observed dramatic, female-specific exacerbation of intestinal inflammation accompanied by significant reductions in intestinal regulatory T cell frequency and function.
[Proceedings of the National Academy of Sciences of the United States of America]
1254621 9ZLZTUEL items 1 apa default asc 1
Celltrion Healthcare announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanding the existing marketing authorisation for the subcutaneous formulation of Remsima® in an additional five indications: for the treatment of patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
There were 154 subjects included in this study: 60 with ulcerative colitis, 19 with Crohn’s disease and 75 in the control group. Colonic biopsy was performed in all subjects. Specimens were incubated with a primary anti-CD83 antibody.